Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02)

被引：0

作者：

Oh, Do-Youn

Lugowska, Iwona A.

Stroyakovskiy, Daniil

Jung, Kyung Hae

Dumas, Olivier

Penkov, Konstantin

Dechaphunkul, Arunee

Oaknin, Ana

Kim, Seung Tae

Starling, Naureen

Chewaskulyong, Busyamas

Charonpongsuntorn, Chanchai

Doroshow, Deborah Blythe

Hsiao, Sheng-Yen

Hung, Yi-Ping

Jung, Lindsey

Kuptsova-Clarkson, Nataliya

Michelini, Flavia

Puvvada, Soham D.

Meric-Bernstam, Funda

机构：

[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[2] Maria Sklodowska Curie Natl Res Inst & Oncol Ctr, Early Phase Clin Trials Dept, Warsaw, Poland

[3] Moscow City Oncol Hosp 62, Moscow, Russia

[4] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea

[5] Hotel Dieu Quebec, Quebec City, PQ, Canada

[6] Clin Hosp RZHD Med, St Petersburg, Russia

[7] Prince Songkla Univ, Dept Med, Med Oncol Unit, Fac Med, Hat Yai, Thailand

[8] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol, Gynaecol Canc Programme, Barcelona, Spain

[9] Samsung Med Ctr, Seoul, South Korea

[10] Royal Marsden NHS Fdn Trust, Gastrointestinal Unit, London, England

[11] Inst Canc Res, London, England

[12] Chiang Mai Univ, Chiang Mai, Thailand

[13] Srinakharinwirot Univ, Dept Internal Med, Med Oncol Unit, Fac Med, Nakhon Nayok, Thailand

[14] Icahn Sch Med Mt Sinai, New York, NY USA

[15] Chi Mei Med Ctr, Div Hematol Oncol, Dept Internal Med, Tainan, Taiwan

[16] Taipei Vet Gen Hosp, Taipei, Taiwan

[17] AstraZeneca, Gaithersburg, MD USA

[18] AstraZeneca, Oncol R&D, Gaithersburg, MD USA

[19] AstraZeneca, Translat Med, Oncol R&D, Waltham, MA USA

[20] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4090

引用

页数：1

共 50 条

[1] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02)
Meric-Bernstam, Funda
Kim, Seung Tae
Parinyanitikul, Napa
Moreno, Alberto
Lin, Chia-Chi
Gornastolev, Dmitry
Chindaprasirt, Jarin
Lugowska, Iwona A.
Stroyakovskiy, Daniil
Jassem, Jacek
Harrison, Michelle L.
Ostwal, Vikas S.
Michelini, Flavia
Jung, Lindsey
Kuptsova-Clarkson, Nataliya
Puvvada, Soham D.
Gan, Hui Kong
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
Meric-Bernstam, F.
Makker, V.
Oaknin, A.
Oh, D. Y.
Banerjee, S.
Martin, A. Gonzalez
Jung, K. H.
Lugowska, I.
Manso, L. M.
Manzano, A.
Melichar, B.
Siena, S.
Stroyakovskiy, D.
Fielding, A.
Ma, Y.
Puvvada, S. D.
Lee, J. Y.
ANNALS OF ONCOLOGY, 2023, 34 : S1273 - S1274
[3] Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
Oh, D-Y.
Meric-Bernstam, F.
Makker, V.
Oaknin, A.
Banerjee, S.
Gonzalez Martin, A.
Jung, K. H.
Lugowska, I.
Manso, L. M.
Manzano, A.
Melichar, B.
Siena, S.
Stroyakovskiy, D.
Fielding, A.
Ma, Y.
Puvvada, S. D.
Lee, J-Y.
ANNALS OF ONCOLOGY, 2023, 34 : S1494 - S1495
[4] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
Meric-Bernstam, Funda
Makker, Vicky
Oaknin, Ana
Oh, Do-Youn
Banerjee, Susana N.
Martin, Antonio Gonzalez
Jung, Kyung Hae
Lugowska, Iwona A.
Manso, Luis
Manzano, Aranzazu
Melichar, Bohuslav
Siena, Salvatore
Stroyakovskiy, Daniil
Anoka, Chiedozie
Ma, Yan
Puvvada, Soham D.
Lee, Jung-Yun
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA3000 - LBA3000
[5] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study
Wysocki, Piotr Jan
Jung, Kyung Hae
Oh, Do-Youn
Doroshow, Deborah Blythe
Artamonova, Elena
Mammatas, Lemonitsa
Su, Po-Jung
Moiseyenko, Vladimir
Penkov, Konstantin
Stroyakovskiy, Daniil
Bartolome, Jorge
Siena, Salvatore
Fielding, Anitra
Jung, Lindsey
Michelini, Flavia
Puvvada, Soham D.
Makker, Vicky
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
Meric-Bernstam, Funda
Makker, Vicky
Oaknin, Ana
Oh, Do-Youn
Banerjee, Susana N.
Martin, Antonio Gonzalez
Jung, Kyung Hae
Lugowska, Iwona A.
Manso, Luis
Manzano, Aranzazu
Melichar, Bohuslav
Siena, Salvatore
Stroyakovskiy, Daniil
Anoka, Chiedozie
Ma, Yan
Puvvada, Soham D.
Lee, Jung-Yun
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
[7] An open-label, multicenter, phase II study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2
Lee, J-Y.
Makker, V.
Oaknin, A.
Oh, D-y.
Anoka, C.
Jung, L.
Simoes, J.
Puvvada, S. D.
Meric-Bernstam, F.
ANNALS OF ONCOLOGY, 2024, 35
[8] An open-label, multicenter, phase II study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2
Lee, J-Y
Makker, V.
Oaknin, A.
Oh, D-Y
Anoka, C.
Jung, L.
Simoes, J.
Puvvada, S. D.
Meric-Bernstam, F.
ANNALS OF ONCOLOGY, 2024, 35 : S1553 - S1553
[9] DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma
Makker, V.
Lee, J-Y.
Oh, D-Y.
Oaknin, A.
Puvvada, S. D.
Cecchi, F.
Mcewen, R.
Michelini, F.
Meric-Bernstam, F.
ANNALS OF ONCOLOGY, 2023, 34 : S239 - S240
[10] A phase II, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select HER2-expressing solid tumors (DESTINY-PanTumor02)
Meric-Bernstam, F.
Anoka, C.
Dobrowolska, A.
Chaudhry, A.
Rowbottom, J.
Gustavson, M.
Puvvada, S.
ANNALS OF ONCOLOGY, 2021, 32 : S1253 - S1254

← 1 2 3 4 5 →